Search the Newsreel

$ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law

NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company’s senior executives for securities fraud after its significant …

ADMA BIOLOGICS CLASS ACTION REMINDER: Bragar Eagel &

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA made false and misleading statements, including engaging in an …

ADMA Biologics Shareholder Alert: ClaimsFiler Reminds

ClaimsFiler is reminding investors who lost over $100,000 in ADMA Biologics, Inc. (NasdaqGM: ADMA) between August 9, 2024, and March 25, 2026, that they have until August 10, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that …

Lost Money on ADMA BIOLOGICS, INC. (ADMA)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

SueWallSt is urging investors who lost money on ADMA Biologics, Inc. (ADMA) to join a class action lawsuit. The suit alleges that ADMA misled investors about ASCENIV revenue growth, with a short-seller report claiming a significant decline instead of the projected increase. The discrepancy …

ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed

Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA), urging investors with substantial losses to contact the firm. The lawsuit alleges that ADMA Biologics misrepresented its financial condition, revenue recognition, inventory distribution, and business practices, including engaging …

ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ADMA Biologics, Inc. for alleged securities law violations, including undisclosed related-party transactions, channel stuffing, and inadequate internal controls. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, …

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to ...

The Rosen Law Firm is encouraging investors of ADMA Biologics, Inc. to join a securities class action lawsuit. Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to move for lead plaintiff. The lawsuit …

ADMA Deadline Alert: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. (ADMA) Investors of Securities Class Action Deadline on August 10, 2026

Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. (ADMA) on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA engaged in channel stuffing to artificially inflate ASCENIV …

Form 4 ADMA Biologics Inc For: 21 July By Investing.com

Investing.com reports a Form 4 filing for ADMA Biologics Inc on July 21. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their beneficial ownership of the company's …

ADMA Lawsuit Notice: ADMA Biologics Channel Stuffing Allegations and 29% Stock Drop Trigger Securities Fraud Class Action

A class action lawsuit has been filed against ADMA Biologics, Inc. and its senior executives for securities fraud, following a significant stock drop. The lawsuit alleges that ADMA engaged in a channel stuffing scheme to inflate revenue growth for its flagship product, ASCENIV, masking …

INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead ADMA Investor Class Action Lawsuit – RGRD Law

SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), …

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged securities fraud, covering investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit claims ADMA made false and misleading statements by failing …

ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

Levi & Korsinsky, LLP is examining the adequacy of ADMA Biologics, Inc.'s risk disclosures and related party reporting between August 9, 2024, and March 25, 2026. The firm alleges that ADMA's reported 20% ASCENIV revenue growth in 2025 was fictitious, masking a 3% decline …

ADMA: Adma Biologics Inc Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock information for Adma Biologics Inc (ADMA), including its current stock price, market capitalization, volume, 52-week high/low, and EPS. It also lists recent news articles concerning securities fraud lawsuits against the company and highlights popular trending stocks and discussions …

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against PicS N.V. (PICS), BitGo Holdings, Inc. (BTGO), and ADMA Biologics, Inc. (ADMA) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC reminds investors of lead plaintiff deadlines for class action lawsuits against PicS N.V. (PICS), BitGo Holdings, Inc. (BTGO), and ADMA Biologics, Inc. (ADMA). The lawsuits allege false statements or failure to disclose material facts by the companies. Investors who suffered …

Form 4 ADMA Biologics Inc For: 17 July By Investing.com

This article reports on a Form 4 filing for ADMA Biologics Inc. dated July 17. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The article provides the company's stock performance (-1.14%) at the time of publication …

ADMA Biologics (NASDAQ: ADMA) grants CFO RSUs and $8.81 options

ADMA Biologics' CFO and Treasurer, Terry Kohler, was granted 85,130 restricted stock units (RSUs) and an option for 136,363 shares at an exercise price of $8.81 per share on July 16, 2026. These equity awards, governed by the ADMA Biologics, Inc. 2022 Equity Compensation …

Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders

Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for shareholders of ADMA Biologics, Inc. (ADMA) who suffered losses. The firm is urging investors to contact them by August 10, 2026, to file a lead plaintiff motion in a class action lawsuit …

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

Robbins LLP is urging investors of ADMA Biologics, Inc. (NASDAQ: ADMA) to contact their firm regarding a class action lawsuit filed against the company. The lawsuit alleges that ADMA Biologics misled investors between August 9, 2024, and March 25, 2026, by engaging in undisclosed …

INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces an investor class action lawsuit against ADMA Biologics, Inc. for alleged violations of the Securities Exchange Act of 1934. Purchasers of ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, …

ADMA DEADLINE: SueWallSt Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline

SueWallSt is reminding investors of ADMA Biologics, Inc. (NASDAQ: ADMA) about an upcoming securities class action deadline. The lawsuit alleges that ADMA falsely certified effective internal controls while concealing "channel stuffing" and an undisclosed related-party distributor, "Genesis BioPharma Services," operating out of its headquarters. …

ADMA Fraud Notice: ADMA Biologics Investors are Reminded to Contact BFA Law about the Filed Securities Fraud Class Action Lawsuit to Recover Investment Losses

ADMA Biologics (NASDAQ:ADMA) is facing a securities fraud class action lawsuit filed by Bleichmar Fonti & Auld LLP. The lawsuit alleges that ADMA engaged in a channel stuffing scheme to inflate its reported 20% growth for 2025 by inducing distributors to stock excess product …

ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Levi & Korsinsky, LLP has issued a shareholder alert regarding a securities class action lawsuit against ADMA Biologics, Inc., naming senior executives as individual defendants. The lawsuit alleges that ADMA's reported ASCENIV revenue growth was inflated by a channel stuffing scheme and undisclosed related …

ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run

ADMA Biologics (ADMA) Stock May Be Undervalued After Fraud Lawsuit Filing

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations

Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts

Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

Weighing ADMA Biologics (ADMA) After A 56% One-Year Share Price Decline

ADMA Biologics sets May 6 earnings webcast for 4:30 p.m. ET

Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?

ADMA Shares Decline Amid Controversy Over Revenue Growth

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump